Research programme: eukaryotic initiation factor 5A-1 modulators - Eloxx Pharmaceuticals
Alternative Names: F5A1 modulators; Factor 5A1 modulatorsLatest Information Update: 04 Jan 2018
At a glance
- Originator Senesco Technologies
- Developer Senesco Technologies; Sevion Therapeutics
- Class
- Mechanism of Action Apoptosis inhibitors; Eukaryotic initiation factor 5A modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Glaucoma; HIV infections; Inflammatory bowel diseases; Ischaemic heart disorders; Septic shock; Type 1 diabetes mellitus
Most Recent Events
- 17 Nov 2014 No development reported - Preclinical for Autoimmune disorders in USA (unspecified route)
- 17 Nov 2014 No development reported - Preclinical for Cancer in USA (unspecified route)
- 17 Nov 2014 No development reported - Preclinical for Inflammatory bowel disease in USA (unspecified route)